Mattsson Jan

Chief Scientific OfficerALBIREO PHARMA, INC. (ALBO) · full profile →Form 4 · filed Mar 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2023Tender(U)36K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2023Disposed to issuer(D)13K0
Mar 2, 2023Disposed to issuer(D)40K0
Mar 2, 2023Disposed to issuer(D)32K0
Mar 2, 2023Disposed to issuer(D)32K0
Mar 2, 2023Disposed to issuer(D)24K0
Mar 2, 2023Disposed to issuer(D)74K0
Mar 2, 2023Disposed to issuer(D)20K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-014736) within minutes of acceptance. Every field above traces to the original document. Verify it directly: